PURPOSE: To evaluate the efficacy and safety of long-term empiric amiodarone therapy in patients with recurrent Sustained Ventricular Tachycardia (SVT) and Chronic Chagasic Myocarditis (CCM). PATIENTS AND METHODS: Thirty-five patients with CCM and SVT, eighteen (51%) of them were refractory to other antiarrhythmic drugs. The Amiodarone loading dose was between 600 and 1200 mg/day, mean of 883 +/- 239 mg/day, from a period of one to four weeks. The maintenance dose was decreasing in the follow-up period, it fell down to 356 +/- 125 mg/day at the end of six to 80 (mean = 27 +/- 20) months. Cumulative, event-free interval curves were generated by the Kaplan-Meier method. Clinical variables were compared with the use of the Student t-test or by means of chi-square tests. RESULTS: The probability to suppress SVT was, 0.62 in 12 months, 0.56 in 24 months and 0.44 in 36 months, with regular use of amiodarone. The probability to the occurrence of sudden death was 0.0 in 12 months, 0.04 in 24 months and 0.11 in 36 months. The stratification of risk to clinical recurrence was significative to the left ventricular disfunction. All patients with functional class III or IV and LV ejection fraction less than 30% at radioisotopic ventriculography had clinical recurrence, while just 30% of patients with functional class I and II have got it (p less than 0.05). Fifteen (42.8%) patients had side effects. The treatment was discontinued in four patients (11.5%). CONCLUSION: The empiric treatment with amiodarone apparently was effective in patients with SVT and CCM and functional class I and II. Patients with functional class III and IV did not get benefits from the treatment. In these cases other therapy must be pointed out.
PURPOSE: To evaluate the efficacy and safety of long-term empiric amiodarone therapy in patients with recurrent Sustained Ventricular Tachycardia (SVT) and Chronic Chagasic Myocarditis (CCM). PATIENTS AND METHODS: Thirty-five patients with CCM and SVT, eighteen (51%) of them were refractory to other antiarrhythmic drugs. The Amiodarone loading dose was between 600 and 1200 mg/day, mean of 883 +/- 239 mg/day, from a period of one to four weeks. The maintenance dose was decreasing in the follow-up period, it fell down to 356 +/- 125 mg/day at the end of six to 80 (mean = 27 +/- 20) months. Cumulative, event-free interval curves were generated by the Kaplan-Meier method. Clinical variables were compared with the use of the Student t-test or by means of chi-square tests. RESULTS: The probability to suppress SVT was, 0.62 in 12 months, 0.56 in 24 months and 0.44 in 36 months, with regular use of amiodarone. The probability to the occurrence of sudden death was 0.0 in 12 months, 0.04 in 24 months and 0.11 in 36 months. The stratification of risk to clinical recurrence was significative to the left ventricular disfunction. All patients with functional class III or IV and LV ejection fraction less than 30% at radioisotopic ventriculography had clinical recurrence, while just 30% of patients with functional class I and II have got it (p less than 0.05). Fifteen (42.8%) patients had side effects. The treatment was discontinued in four patients (11.5%). CONCLUSION: The empiric treatment with amiodarone apparently was effective in patients with SVT and CCM and functional class I and II. Patients with functional class III and IV did not get benefits from the treatment. In these cases other therapy must be pointed out.
Authors: Rosália Morais Torres; Dalmo Correia; Maria do Carmo Pereira Nunes; Walderez O Dutra; André Talvani; Andréa Silvestre Sousa; Fernanda de Souza Nogueira Sardinha Mendes; Maurício Ibrahim Scanavacca; Cristiano Pisani; Maria da Consolação Vieira Moreira; Dilma do Socorro Moraes de Souza; Wilson de Oliveira Junior; Silvia Marinho Martins; João Carlos Pinto Dias Journal: Mem Inst Oswaldo Cruz Date: 2022-06-06 Impact factor: 2.747
Authors: Augusto Cardinalli-Neto; Adalberto M Lorga-Filho; Elissandro F Silva; Renata P Lima; Eduardo Palmegiani; Reinaldo B Bestetti Journal: Int J Cardiol Heart Vasc Date: 2015-10-19
Authors: Silvia M Ayub-Ferreira; Sandrigo Mangini; Victor S Issa; Fátima D Cruz; Fernando Bacal; Guilherme V Guimarães; Paulo R Chizzola; Germano E Conceição-Souza; Fabiana G Marcondes-Braga; Edimar A Bocchi Journal: PLoS Negl Trop Dis Date: 2013-04-25